Description

Camurus AB (publ), a pharmaceutical firm established in Lund, Sweden, in 1991, specializes in creating and bringing to market therapeutic solutions for debilitating and long-term health conditions. The company operates globally, with a presence in Europe, Australia, the United States, Japan, and other international markets. Its current commercial offerings include Buvidal and Brixadi, both injectable buprenorphine formulations for managing opioid dependence and opioid use disorder, respectively. Camurus also supplies episil oral liquid, a medical device engineered to relieve inflammation and discomfort in the mouth. The company maintains a dynamic product pipeline with numerous compounds advancing through different clinical stages. Noteworthy candidates include CAM2038 for chronic pain; CAM2029, undergoing Phase III trials for acromegaly and neuroendocrine tumors, and Phase II for polycystic liver diseases; and CAM2043, which is in Phase I for pulmonary arterial hypertension and Phase II for Raynaud's phenomenon. Further programs encompass CAM2032 (Phase II for prostate cancer), CAM4072 (Phase III for genetic obesity disorders), and CAM4071 (Phase I for an endocrine disorder). Early-stage research is also underway for CAM2047, targeting chemotherapy-induced nausea and vomiting, and CAM2048, aimed at postoperative pain relief.